CA2204144A1 - Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase - Google Patents

Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase

Info

Publication number
CA2204144A1
CA2204144A1 CA002204144A CA2204144A CA2204144A1 CA 2204144 A1 CA2204144 A1 CA 2204144A1 CA 002204144 A CA002204144 A CA 002204144A CA 2204144 A CA2204144 A CA 2204144A CA 2204144 A1 CA2204144 A1 CA 2204144A1
Authority
CA
Canada
Prior art keywords
obn
trp
tyr
ala
cbz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002204144A
Other languages
French (fr)
Inventor
Francis J. Tinney
Judith Sebolt-Leopold
Gary Louis Bolton
Daniele Leonard
Donald Hupe
Tomi Sawyer
Alfred Campbell
Richard Gowan
John Cooke Hodges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2204144A1 publication Critical patent/CA2204144A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Inhibitors of protein:farnesyl transferase enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling tissue proliferative diseases, including cancer and restenosis.

Description

W O96/17861 PCT~US95/14010 S~3~ u1~:~ TETRA- AND PEN-TAPEPTIDE INHIBITORS
OF PROTEIN:FARNESYL TRANSFERASE

FIELD OF THE 1Nv~N11ON
The present invention pertains to a number of compounds which can be used in the medicinal field to treat, prophylactically or otherwise, uncontrolled or abnormal proliferation of human tissues. More specifically, the present invention pertains to a number of compounds which act to inhibit the farnesyl transferase enzyme that has been determined to activate ras proteins which in turn activate cellular division and are implicated in cancer and restenosis.

BACKGROUND OF THE INv~N11ON

Ras protein (or p21) has been ex~m;ne~ extensively because mutant forms are found in 20~ of most types of human cancer and greater than 50~ of colon and pancreatic carcinomas (J. B. Gibbs, Cell 65, l (l99l), T. Cartwright, et al., Chimica Oqgi l0, 26 (1992)).
These mutant ras proteins are deficient in the capability for feedback regulation that is present in native ras and this deficiency is associated with their W O96/17861 PCTrUS95/14010 oncogenic action since the ability to stimulate normal cell di~icion can not be controlled by the normal endogenous regulatory cofactors. The recent discovery that the transforming activity of mutant ras is critically dependent on posttranslational modifications (J. Gibbs, et al., Microbiol. Rev. 53, 171 (1989)) has un~eiled an important aspect of ras function and identified novel prospects for cancer therapy.
In addition to cancer, there are other conditions of uncontrolled cellular proliferation that are related to excessive expression and/or function of native ras proteins. Post surgical vascular restenosis is such a condition. The use of various surgical revascularization techniques such as saphenous vein bypass grafting, endarterectomy and translllm; n~l coronary angioplasty is often accn~p~n;ed by complications due to uncontrolled growth of neointimal tissue, known as restenosis. The biochemical causes of restenosis are poorly understood and numerous growth factors and protooncogenes have been implicated (A. J.
Naftilan, et al., Hypertension 13, 706 (1989) and J.
Clin. Invest. 83, 1419; G. H. ~ibbons, et al., Hypertension 14, 358 (1989); T. Satoh, et al., Mollçc, Cell. Biol. 13, 3706 (1993)). The fact that ras proteins are known to be involved in cell division processes makes them a candidate for intervention in many situations where cells are di~iding uncontrollably. In direct analogy to the inhibition of mutant ras related cancer, blockade of ras dependant processes has the potential to reduce or eliminate the inappropriate tissue proliferation associated with restenosis, particularly in those instances where normal ras expression and/or function is exaggerated by growth stimulatory factors.
Ras functioning is dependent upon the modification of the proteins in order to associate with the inner WO96/17861 PCT~S95/14010 face of plasma membranes. Unlike other membrane-associated proteins, ras proteins lack conventional tr~ncm~mhrane or hydrophobic sequences and are initially synthesized in a cytosol soluble form. Ras protein membrane association is triggered by a series of posttranslational processing steps that are signaled by a carboxyl te~m;n~l amino acid consensus sequence that i8 recognized by protein:farnesyl transferase.
This consensus se~uence consists of a cysteine residue located four amino acids from the carboxyl termln followed by two lipophilic amino acids and the C-terminal residue. The sulfhydryl group of the cysteine residue is alkylated by farnesyl pyrophosphate in a reaction that is catalyzed by protein:farnesyl transferase. Following prenylation, the C-t~rmin~l three amino acids are cleaved by an endoprotease and the newly exposed alpha-carboxyl group of the prenylated cysteine is methylated by a methyl transferase. The enzymatic processing of ras proteins that begins with farnesylation enables the protein to associate with the cell membrane. Mutational analysis of oncogenic ras proteins indicate that these posttranslational modifications are essential for transforming activity. Replacement of the consensus sequence cysteine residue with other amino acids gives a ras protein that is no longer farnesylated, fails to migrate to the cell membrane and lacks the ability to stimulate cell proliferation (J. F. Hancock, et al., Cell 57, 1617 (1989), W. R. Schafer, et al., Science 245, 379 (1989), P. J. Casey, Proc. Natl. Acad. Sci.
USA 86, 8323 ~1989)).
Recently, protein:farnesyl transferases (PFTs, also referred to as farnesyl:protein transferases) have been identified and a specific PFT from rat brain was purified to homogeneity (Y. Reiss, et al., Bioch. Soc.
Trans. 20, 487-88 (1992)). The enzyme was W O96/17861 PCTrUS95/14010 characterized as a heterodimer composed of one alpha-subunit (49 kDa) and one beta-subunit (46 kDa), both of which are required for catalytic activity. High level expression of m~mmAlian PFT in a baculovirus system and purification of the recombinant enzyme in active form has also been accomplished (W.-J. Chen, et al., ~.
Biol. ~hem. ~68, 9675 (1993)).
In light of the foregoing, the discovery that the function of oncogenic ras proteins is critically dependent on their posttranslational processing pro~ides a means of cancer chemotherapy through inhibition of the processing enzymes. The identification and isolation of a protein:farnesyl transferase that catalyzes the addition of a farnesyl group to ras proteins provides a promising target for such intervention. Recently it has been deter~l n~
that prototypical inhibitors of PFT can inhibit ras processing and reverse cancerous morphology in tumor cell models (N. E. Kohl, et al., Science 260, 1934 (1993), G. L. James, et al., Science 260, 1937 (1993), A. M. Garcia, et al., J. Biol. Chem. 268, 18415 (1993)). Thus, it is possible to prevent or delay the onset of cellular proliferation in cancers that exhibit mutant ras proteins by blocking PFT. By analogous logic, inhibition of PFT would provide a potential means for controlling cellular proliferation associated with restenosis, especially in those cases wherein the expression and/or function of native ras is overstimulated.
PCT Application WO91/16340 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula CAAX.
European Patent Application 0461869 discloses cysteine cont~;n;ng tetrapeptide inhibitors of PFT of the formula Cys-Aaal-Aaa2-Xaa.

W O 96/17861 PCTrUS95/14010 European Patent Application 0520823 discloses cysteine cont~; n; ng tetrapeptide inhibitors of PFT of r the formula Cys-Xaal-dXaa2-Xaa3.
European Patent Application 0523873 discloses cysteine cont~; n; ng tetrapeptide inhibitor~ of PFT of the formula Cy9 -Xaal-Xaa2-Xaa3.
European Patent Application 0528486 discloses cysteine cont~;n;ng tetrapeptide amides inhibitors of PFT of the formula Cys-Xaal-Xaa2-Xaa3-NRR1.
European Patent Application 0535730 discloses pseudotetrapeptide inhibitors of PFT of the following two formulas:

X R2 o )--~_,ZH
H ~ H ~ JI~H ~ OH

HS Y R O

_ H ~ 3 H

HS Y R o European Patent Application 0535731 (US 5,238,922) discloses esters of pseudotetrapeptide inhibitors of PFT of the formula:

X R2 o )--~_,ZH
H NR ~ H ~ N ~ N ~ OR
Y R O
HS

US 4,035,348 discloses tetrapeptide antagonists of luteinizing hormone releasing factor of the formula CA 02204144 1997-04~30 W O 96117861 PCTrUS95/14010 A-Rl-Tyr(benzyl)-Ser(benzyl)-D-Ala-R2, wherein one of the definitions of R1 i8 ~-His(benzyl).
US 4,043,993 discloses pentapeptide antagonists of luteinizing hormone releasing factor of the formula X-R-Tyr(benzyl)-Ser(benzyl)-Rl-Y, wherein one of the definitions of R i8 His(benzyl~.
US 4,062,835 discloses pentapeptide antagonists of luteinizing hormone releasing factor of the formula X-R-Tyr(methyl)-Ser(benzyl)-R1-Y, wherein one of the definitions of R is His(benzyl).
Compounds disclo9ed in the above references do not disclose or suggest a novel combination of structural variations found in the present invention described hereinafter.
SUMMARY 0~ THE I~V~N110N

Accordingly, the present in~ention is a substituted tetra- or pentapeptide compound of Formula I:

(CH2)n Rl 1~l (CH2)n A-N ~ N ~ N ~ C-D-E
R O (ICH2)n R O
R

wherein n = 1 or 2;
A = -COR2, -CO2R2, -CONHR2, -CSR2, -C(S)R2, -C(S)NHR2, or H;
wherein R2 is alkyl, -(CH2)m-cycloalkyl, -(CH2)m-aryl, -(CH2)m-heteroaryl, and m = 0, 1, 2, or 3;
R = independently H or Me;
Y = independently H or Me;
Z = independently H or Me;

W O96/17861 PCTrUS95/14010 4' -7-R4 = ~

wherein R4 = H or Me;
-SR4 , wherein R4 = H, alkyl, trityl, or heteroaryl;
S
R5 = ~ R5~

wherein R5 = H , - OH , -O-alkyl, alkyl, -CO-aryl, - ( CH2 ) m~ aryl, -O(CH2) m~ cycloalkyl, -O(CH2) m- aryl, - O ( CH2 ) m- heteroaryl, - OPO3R 2, - CH2PO3R 2 ~
-CF2Po3R5 2~ or -CFHPo3R5 2~ wherein R5 i8 located at either the ortho, meta, or para position and R5 = H, alkyl, alkylaryl, or cyclohexyl, and m is as described above;
-CooR7, wherein R7 = H, Me, t-butyl, or benzyl;
-SR8, wherein R8 = H or trityl;
R6 = _oR6 , wherein R6 = H, benzyl, -Po3R5 2~ wherein R5 is as described above;
-CH2-R9, wherein R9 = -Po3R5 2~ wherein R5 is as described above;
- SR6 , wherein R6 = H, benzyl, or trityl;
C = Gly, Ala, Val, Leu, Ile, Phe, Tyr, Tyr(OMe), Pgl, homoPhe, Trp, Trp(Me), or Trp (CHO);
D = Gly, Ala, or absent;
E = - COOH, - CONH2, - CO~UNu2, - CONHR10, or -C02R1~
wherein Rl0 = H, alkyl, -(CH2)m-cycloalkyl, -(CH2)m-aryl, -(CH2)m-heteroaryl, and m is as described above; an isomer or a ~h~rm~ceutically acceptable salt thereof.
The present invention is also directed to the use of a compound of Formula I, or a ph~rm~ceutically acceptable salt therefrom, to inhibit the activity of a protein:farnesyl transferase enzyme aq a method for treating tissue proliferative diseases.
A further embodiment of the present invention is the use of a pharmaceutical composition including an -W O96/17861 PCTrUS95/14010 effecti~e amount of a compound of Formula I as a method for the treatment of cancer.
A still further embodiment of the present invention is the use of a ph~rm~ceutical composition including an effective amount of a compound of Formula I as a method for the treatment of restenosis.
A still further embodiment of the present invention is a pharmaceutical composition for ~mi n; stering an effecti~e amount of a compound of Formula I in unit dosage form in the treatment methods mentioned above.
A final embodiment of the present invention pertains to methods for the preparation of compounds of Formula I by solid phase synthesis and solution phase synthesis.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the compounds of Formula I, the term "alkyl n means a straight or branched hydrocarbon radical ha~ing from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like.
The term n cycloalkyl" means a saturated hydrocarbon ring which contains from 3 to 10 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ~m~ntyl, and the like.
The term n aryl n means an aromatic ring which is a phenyl, 5-fluorenyl, 1-naphthyl or 2-naphthyl group, unsubstituted or substituted by 1 to 3 substituents selected from alkyl, O-alkyl and S-alkyl, -OH, -SH, -F, -Cl, -Br, -I, -CF3, -NO2, -NH2, -NHCH3, -N(CH3) 2' -NHCO-alkyl, -(CH2)mCO2H, -(CH2)mCO2-alkyl, -(CH2)mSO3H, -(cH2)mpo3H2 -(cH2)mPo3(alkyl)2l ~(CH2)mS~2NH2' and CA 02204144 1997~04~30 WO96/17861 pcT~sssll4olo -(CH2)mSO2NH-alkyl wherein alkyl is defined as above and m = 0, 1, 2, or 3.
The term "alkylaryl n means alkyl as defined above and aryl as defined above, for example, benzyl.
The term n heteroaryl" means a heteroaromatic ring which i9 a 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5-, 6- or 7-indolyl group, substituted or unsubstituted by 1 or 2 substituents from the group of substituents described above for aryl.
The following table provides a list of abbreviations and definitionc thereof used in the present invention.

W O96/17861 PCTrUS95/14010 Abbreviation Amino Acid Ala Alanine Arg Arginine Asn Asparagine Asp Aspartic acid Cys Cysteine Glu Glutamic acid Gln Glut~m;ne Gly Glycine His Histidine Ile Isoleucine Leu Leucine Ly~ Ly~ine Met Methionine Phe Phenyl~l ~n; ne Pro Proline Ser Serine Thr Threonine Trp Tryptophan Tyr Tyrosine Val Valine Abbreviationt Modified and Unu~ual Amino Acid Aaa-CO2R An amino acid ester, for examples:
Gly-CO2Me is Glycine, methyl ester; D-Ala-CO2Me is D-Alanine, methyl ester.

30 If the optical activity of the amino acid i~ other than L(S), the amino acid or abbreviation i~ preceded by the ~ u~,iate configuration D(R) or D~(RS).

W O 96/17861 ~ PCTrUS95/14010 Abbreviation~ Modified and Unusual Amino Acid (continued) Aaa-CONHR An amino acid amide, for examples:
D-Ala-CONHEt is D-Alanine, N-ethyl amide; Trp-CONH2 i8 Tryptoph~n~m;de.
3Hyp 3-Hydroxyproline 4Hyp 4-Hydroxyproline Hcy Homocysteine N~a Norvaline Nle Norleucine Orn Ornithine Bal Beta-alanine (or 3-aminopropionic acid) Abu 4-Aminobutyric acid Ahe 7-Aminoheptanoic acid Acp 6-Aminocaproic acid Aoc 8-Aminooctanoic acid Apn 5-Aminopentanoic acid Bpa (4-Benzoylphenyl)alanine Chx 3-Cyclohexylalanine (or Hexahydrophenylalanine) Cit Citrulline His(1-Me) 1-Methyl-histidine (or N( T ) - Methyl-histidine~
His(Tr) 1-Triphenylmethyl-histidine (or N(~)-Trityl-histidine) homoPhe 2-Amino-4-phenylbutanoic acid (or Homophenylalanine) homoTyr 2-Amino-4-(4-hydroxyphenyl)butanoic acid (or Homotyrosine) If the optical activity of the amino acid i8 other than L(S), the amino acid or abbreviation i~ preceded by the appropriate configuration D(R) or DL(RS).

W O96117861 PCTrUS95/14010 Abbreviation Modified a~d Unusual Amino Acid (continued) homoTyr(OBn) 2-Amino-4-~4-(phenylmethoxy)phenyl]-butanoic acid (or O-Benzyl-homotyrosine) 1-Nal 3-(1'-Naphthyl)alanine 2-Nal 3-(2'-Naphthyl)alanine Pen Penicill~m; ne Phe(3-OBn) (3-Benzyloxyphenyl)alanine Phe(4-Ph) 3-(l,l'Biphen-4-yl)alanine (or 4-Phenyl-phenylalanine) Pgl Phenylglycine Pyr 2-Amino-3-(3-pyridyl)-propanoic acid (or 3-Pyridylalanine) Ser(OBn) O-Benzyl-serine Thr(OBn) O-Benzyl-threon;ne Tic 1,2,3,4-Tetrahydro-3-isoquinoline-carboxylic acid Tyr(OMe) O-Methyl-tyrosine Tyr(OEt) O-Ethyl-tyrosine Tyr(OBn) O-Benzyl-tyrosine (~-Me)Tyr(OBn) 2-Amino-3-(4-benzyloxyphenyl)-2-methyl-propionic acid (or ~-Methyl-O-benzyl-tyrosine) (N-Me)Tyr(OBn) N-Methyl-O-benzyl-tyrosine Trp(For) Nin-Formyltryptophan Abbreviation Mercapto Acids Maa Mercaptoacetic acid Mba 4-Mercaptobutyric acid Mpa 3-Mercaptopropionic acid If the optical acti~ity of the amino acid i8 other than L(S), the amino acid or abbre~iation i~ preceded by the a~Lu~iate 35 configuration D(R~ or DL(RS).

WO96/17861 PCT~S95/14010 Abbreviation Protecting Group Ac Acetyl Ada l-A~mAntyl acetic acid Adoc ~mAntyloxycarbony Bn Benzyl MeBn 4-Methylbenzyl Cbz Benzyloxycarbonyl 2-Br-Cbz ortho-Bromobenzyloxycarbonyl 2-Cl-Cbz ortho-Chlorobenzyloxycarbonyl Bom Benzyloxymethyl Boc tertiary Butyloxycarbonyl Dnp 2,4-Dinitrophenyl For Formyl Fmoc 9-Fluorenylmethyloxycarbonyl N02 Nitro Tos 4-Toluenesulfonyl (tosyl) Tr Triphenylmethyl (trityl) Abbreviation Sol~ents and Reaqents HOAc Acetic acid CF3SO2H Trifluoromethanesulfonic acid DCM Dichloromethane DCC N,N'-Dicyclohexylcarbodiimide DIC N,N'-Diisopropylcarbodiimide DIEA N,N-Diisopropylethylamine DMAP 4-Dimethylaminopyridine DMF N,N'-Dimethylformamide EDAC N-Ethyl-N'-Dimethylaminopropylcarbo-diimide EtOAc Ethyl acetate Et2O Diethyl ether HCl Hydrochloric acid HF Hydrofluoric acid HOBT l-Hydroxybenzotriazole KOH Potassium hydroxide MeCN Acetonitrile CA 02204l44 l997-04-30 W O96/17861 PCT~US95/14010 Abbreviation Solvents and Reaqents (continued) MeOH Methanol NHOS N-Hydroxysuccinimide NMP N-Methylpyrrolidone iPrOH i80- Propanol TFA Trifluoroacetic acid Abbreviation Solid Phase Pçptide Synthesis Resins HMP Resin 4-(Hydroxymethyl)-phenoxymethyl-poly styrene resin MBHA Resin Methylbenzhydrylamine resin PAM Resin 4-(Hydroxymethyl)-phenylacetamidomethyl-polystyrene resin 2-Cl-Tr Resin 2-Chlorotrityl-polystyrene resin NH2- Rink Resin 4-(amino-(2',4'-dimethoxyphenyl)-methyl)-phenoxymethyl-polystyrene resin Abbreviation Biological Reaqents FPP Farnesyl pyrophosphate PFT Protein:farnesyl transferase DTT Dithiothreitol BSA Bovine serum albumin Abbreviation Miscellaneous coR2 1~l CONHR
~5 -CNHR2 cSR2 lSI

CA 02204144 1997-04~30 W O 96/17861 PCTrUS95/14010 Abbre~iation Mi~cellaneou~ (continued) C(S)OR2 S

C ( S ) NHR2 11 CONH2 1~l CONHNH2 1~l - CN~H2 ll Preferred compounds of the invention are designated by Formula II:

Rl7 R16 (CH2)n.lR ~ (CH2) 7~ 7~c -D'-E' II

R O (CH2)nl R ~
~13 whereln n' = 1 or 2;
A' = -COR2 , -C02R2 , or -CONHR2 , wherein R2 = alkyl, -(CH2)m-aryl, -(CH2)m-heteroaryl, and m = 0, 1, or 2;
R = independently H or Me;
3 5 Y = independently H or Me;
Z = independently H or Me;

R12 = ~
~ N
wherein R12 = H or Me;

W O96/17861 PCTrUS95114010 -SR12 , wherein R12 = H or alkyl;

R13 = ~ Rl3 wherein R13 = H, -OH, -O-alkyl, alkyl, -CO-aryl, benzyl, -O-benzyl, wherein Rl3 is located at either the ortho, meta, or para position;
-oPo3R142, -CH2Po3Rl42, or -CF2Po3Rl42, wherein R14 - H
or alkyl;
-CooR15, wherein R15 = H, Me, t-butyl, or benzyl;
R16 = -OR16 , wherein R16 = H, benzyl, -Po3R142, wherein R14 is as described above;
-CH2-R16 , wherein R16 = -Po3R142, wherein R14 is as described above;
-SR16 , wherein R16 = H or benzyl;
C' = Ala, Trp, Trp(Me), or Trp(CHO);
D' = Gly, Ala, or absent;
E' = -COOMe, -CONH2, -CONHNH2, -COOH or -CONH-alkyl; an isomer or a ph~rm~ceutically acceptable salt thereof.
Other preferred compounds of the present invention are those of Formula I as defined above wherein A is Cbz, BnNHCO, R is H and n is 1 or 2; or as defined above wherein R4 is H

~ ~ ,-SH and Y is H;
N

or as defined above wherein wherein R5 is ~ R

wherein R5 is H, -OH, -OBn, -OPO3H2, -CH2 PO3H2, -CH2PO3Et2, -CF2PO3H2, or wherein R5 = -COOH, and Z is H;
or as defined above wherein R6 is -OBn, -OH, -SH, or -OP03H2; or as defined above wherein C is Trp or Ala;

WO96/17861 PCT~S95114010 or as defined above wherein D i8 Ala, Gly, or absent;
or as defined above wherein E is -COOH, -CONH2, -COOMe, -CONHEt, -CONHNH2, or -CONHMe.
Most preferred compounds of the invention include the following:
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2;
Cbz-Hic-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHMe;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHEt;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHNH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CO2Me;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala;
Cbz-Hi~-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHMe;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHEt;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHNH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-C02Me;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHMe;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHEt;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHNH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CO2Me;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly;
Cbz-His-Tyr-Ser(OBn)-Trp-D-Ala-CONH2;
Cbz-His-Tyr(OBn)-Ser-Trp-D-Ala-CONH2;
Cbz-His-Phe-Ser(OBn)-Trp-D-Ala-CONH2;
Cbz-His-Phe-Ser(OBn)-Trp-Ala-CONH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Ala-D-Ala-CONH2;
Cbz-D-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2;
Cbz-His-D-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-CO2Me;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-CONH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-D-Ala-CO2Me;
Cbz-His-Tyr(OBn)-Ser(OBn)-D-Ala;
Cbz-D-His-Tyr(OBn)-Ser(OBn)-Trp-CO2Me;
C~z-His-D-Tyr (OBn) -Ser (OBn) -Trp-CO2Me W O96/17861 PCTrUS95/14010 Cbz-His-Tyr(OBn)-Cys-Trp-CONH2;
BnNHCO-His-Tyr(OBn)- Cy8- Trp-CONH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHMe;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHEt;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CON~N~2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CO2Me;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHMe;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHEt;
BnNHCO-Hic-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHNH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CO2Me;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHMe;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHEt;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHNH2;
' BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CO2Me;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly;
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CONH2;
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CONHMe;
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CONHEt;
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CONHNH2;
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CO2Me;
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala;
Cbz-His-Tyr(OBn)- Cy8- Trp-Ala-CONH2;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala-CONHMe;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala-CONHEt;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala-CONHNH2;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala-CO2Me;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala;
Cbz-His-Tyr(OBn)-Cys-Trp-Gly-CONH2;
Cbz-His-Tyr(OBn)-Cys-Trp-Gly-CONHMe;
Cbz-His-Tyr(OBn)-Cys-Trp-Gly-CONHEt;
Cbz-His-Tyr(OBn)-Cys-Trp-Gly-C0NHNH2;

WO96/17861 PCT~S95/14010 Cbz-His-Tyr(OBn)-Cys-Trp-Gly-CO2Me;
Cbz-His-Tyr(OBn)-Cy9-Trp-Gly;
BnNHCO-His-Tyr(OBn)-Cy9-Trp-D-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Cy9-Trp-D-Ala-CONHMe;
S BnNHCO-His-Tyr(OBn)-Cy9-Trp-D-Ala-CONHEt;
BnNHCO-His-Tyr(OBn)-Cys-Trp-D-Ala-CONHNH2;
BnNHCO-His-Tyr(OBn)-Cy9-Trp-D-Ala-CO2Me;
BnNHCO-His-Tyr(OBn)-Cy9-Trp-D-Ala;
BnNHCO-His-Tyr(OBn)-Cy9-Trp-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Cy9-Trp-Ala-CONHMe;
BnNHCO-His-Tyr(OBn)-Cy9-Trp-Ala-CONHEt;
BnNHCO-His-Tyr(OBn)-Cy9-Trp-Ala-CONHNH2;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Ala-CO2Me;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Ala;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Gly-CONH2;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Gly-CONHMe;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Gly-CONHEt;
BnNHCO-His-Tyr(OBn)-Cy9-Trp-Gly-CONHNH2;
BnNHCO-His-Tyr(OBn)-Cy9-Trp-Gly-CO2Me;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Gly;
Cbz-Cys-Tyr(OBn)-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-Tyr(OPO3H2)-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-p(CH2PO3H2)Phe-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-p(CH2PO3Et2)Phe-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-p(CF2PO3H2)Phe-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-Glu-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-A9p-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-Tyr(OBn)-Ser(OPO3H2)-Trp-DAla-CONH2;
Cbz-His-Tyr(OPO3H2)-Cys-Trp-DAla-CONH2; and Cbz-His-Tyr(OPO3H2)-Ser(OBn)-Trp-CONH2.

CA 02204l44 l997-04-30 GENBRAL METHODS FOR THE PREPARATION, EVALUATION
AND USE OF COMPOUNDS OF FORMUhA I

The compounds of Fonmula I may be prepared by solid phase peptide synthesis on a peptide synthesizer, for example, an Applied Biosystems 430A peptide synthesizer using activated esters or anhydrides of Boc or Fmoc protected amino acids, acid chlorides, isocyanates, isothiocyanates, etc, on PAM, M~HA, or NH2-Rink resins with solution phase modifications to the carboxyl termlnll~ as appropriate. Methodology for the solid phase synthesis of peptides is widely known to those skilled in the art thereof (see, for example:
J. M. Stewart and J. D. Young in Solid Phase Peptide Synthesis; Pierce Chemical Co.; Rockford, IL (1984);
G. B. Fields and R. L. Noble, Int. J. Peptide Protein Res. ~5, 161-214 (1990)). Additionally, the compounds of Formula I may also be prepared by conventional solution peptide synthesis, substituting Aml~es~ acid chlorides, isocyanates, etc, for amino acid derivatives where appropriate. Methods for solution phase synthesis of peptides are widely known to those skilled in the art (see, for example, M. Bodanszky, Principles of Peptide Synthesis, Springer-Verlag (1984)). For both of the synthetic methods described above appropriate consideration is given to protection and deprotection of reactive functional groups and to the sequence of synthetic steps. Knowledge of the use of common protecting groups and strategy for the assembly of complex organic molecules are within the usual realm of expertise of a practitioner of the art of organic chemistry (see, for example: T. W. Greene and P. G. M
Wuts, Protective Groups in Organic Chemistry, John Wiley and Sons (1991); E. J. Corey and X.-M. Cheng, The Loqic of Chemical Synthesis, John Wiley and Sons (1989)).

W O 96/17861 PCTrUS95/14010 The homogeneity and composition of the resulting compounds is verified by RP-HPLC, capillary electrophoresis, thin layer chromatography (TLC), proton nuclear magnetic resonance spectrometry ~NMR), amino acid analysis, chemical ionization mass spectrometry (CI-MS), fast atom bombardment mass spectrometry (FAB-MS) and electrospray mass spectrometry (ES-MS).
The compounds of ~onmula I are capable of further forming both pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope of the present invention.
ph~rm~ceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glucamine (see, for example, S. M. Berge, et W O96/17861 PCTrUS95/14010 al., "Pharmaceutical Salts, n Journal of Pha ~ ceutical Science 66, 1-19 (1977)).
The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional m~nner. Preferably a compound of Formula I can be converted to an acidic salt by treating with an aqueous solution of the desired acid, such that the resulting p~ is less than 4. The solution can be passed through a C18 cartridge to absorb the compound, washed with copious amounts of water, the compound eluted with a polar organic solvent such as, for example, methanol, acetonitrile, and the like, and isolated by concentrating under reduced pressure followed by lyophilization. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional mAnn~r or as above. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equi~alent to their respective free base for purposes of the present invention.
ph~rm~ceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic ~3m;neS. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable ~m; n~s are N,N'-dibenzylethyl~nerl; ~mt n~, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethyl~ne~; ~m; ne, N-methylglucamine, and procaine (see, for example, S. M. Berge, et al., n Pharmaceutical Salts", Journal of Pharmaceutical Science 66, 1-19 (1977)).
The base addition salts of said acidic compounds are prepared by contacting the free acid form with a Wo96/17861 PCT~S95/14010 sufficient amount of the desired base to produce the salt in the conventional m~nner. Preferably, a compound of Formula I can be converted to a base salt by treating with an aqueous solution of the desired base, 8uch that the re9ulting pH is greater than 9.
The solution can be pa9sed through a C18 cartridge to absorb the compound, wa9hed with copious amounts of water, the compound eluted with a polar organic solvent such as, for example, methanol, acetonitrile and the like, and isolated by concentrating under reduced pressure followed by lyophilization. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner or a9 above. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the 9alts are equivalent to their respective free acid for purposes of the present invention.
Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof.
The PFT inhibitory activity of compounds of Formula I was assayed in 30 mM potassium phosphate buffer, pH 7.4, cont~;n;ng 7 mM DTT, 1.2 mM MgCl2, 0.1 mM leupeptin, 0.1 mM pepstatin, and 0.2 mM
phenylmethylsulfonyl fluoride. Assays were performed in 96 well plates tWallec) and employed solutions W O 96/17861 PCTrUS95/14010 composed of varying concentrations of a compound of Formula I in 100~ DMSO. Upon addition of both substrates, radiolabeled farnesyl pyrophosphate ([1-3H], specific activity 15-30 Ci/mmol, final concentration 0.12 ~M) and (biotinyl)-Ahe-Tyr-Lys-Cys-Val-Ile-Met peptide (final concentration 0.1 ~M), the enzyme reaction was started by addition of 40-fold purified rat brain farnesyl protein transferase. After incubation at 37~C for 30 minutes, the reaction was terminated by diluting the reaction 2.5-fold with a stop buffer cont~;nlng 1.5 M magnesium acetate, 0.2 M
H3P04, 0.5~ BSA, and strepavidin beads (Amersham) at a concentration of 1.3 mg/mL. After allowing the plate to settle for 30 minutes at room temperature, radioactivity was quantitated on a microBeta counter (model 1450, Wallec).
As shown below in Table I, compounds of Formula I
show IC50 values of 0.5 to 1000 nM in the assay discussed above and are thus valuable inhibitors of protein:farnesyl transferase enzyme which may be used in the medical treatment of tissue proliferative diseases, including cancer and restenosis.

CA 02204l44 l997-04-30 W O96/17861 PCT~US95/14010 TABLE I
Peptide IC50 (~M) Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-DAla-CONH2 0.017 Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-DAla-CONHEt Q.230 Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-DAla-CONHNH2 0.062 Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-DAla-CO2Me 0.019 Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-DAla-COOH 0.048 Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-NH2 0.015 Cbz-His-Tyr-Ser(OBn)-Trp-DAla-NH2 0.040 Cbz-His-Tyr(OBn)-Ser-Trp-DAla-NH2 1.8 Cbz-His-Phe-Ser(OBn)-Trp-DAla-NH2 0.010 Cbz-Hi~-Tyr(OBn)-Ser(OBn)-Ala-DAla-NH2 0.33 Cbz-DHis-Tyr(OBn)-Ser(OBn)-Trp-DAla-NH2 ~.12 Cbz-His-DTyr(OBn)-Ser(OBn)-Trp-DAla-NH2 0.039 Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-CO2Me 0.115 Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-NH2 0.083 Cbz-His-Tyr(OBn)-Ser(OBn)-DAla-CO2Me 0.142 Cbz-His-Tyr(OBn)-Ser(OBn)-DAla-COOH 0.404 Cbz-His-Tyr(OBn)-Cys-Trp-DAla-NH2 0.004 Cbz-Hi~-Tyr(OPO3H2)-Ser(OBn)-Trp-DAla-NH2 0.009 The compounds of the present invention can be prepared and ~m; n; stered in a wide variety of oral, rectal, and parenteral dosage forms. Thus, the compounds of the present invention can be A~min;stered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be ~m; n; stered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be ~m; n; gtered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the acti~e component, either a compound of Formula I or a corresponding ph~rm~ceutically acceptable salt of a compound of Formula I.

W O96/17861 PCTrUS95/14010 For preparing ph~rmAceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid.
Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided Qolid which is in a mixture with the finely divided active component.
In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
The powders and tablets preferably contain from 5 or 10 to about 70 percent of the active compound.
Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation~ is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral ~Am;n; stration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into W096/17861 PCT~S95/14010 convenient sized mold8, allowed to cool, and thereby to solidify.
~ Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral ~m; n;stration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses cont~;n;ng appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package cont~;n;ng discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

W O96/17861 PCTrUS95/14010 The guantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 100 mg preferably 0.5 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.
In therapeutic use as inhibitors of PFT, the compounds utilized in the ph~rm~ceutical methods of this invention are A~m; n; stered at the initial dosage of about 0.01 mg/kg to about 20 mg/kg daily. A daily dose range of about 0.01 mg/kg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the lS compound being employed. Determ;n~tion of the proper dosage for a=particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and ~m; n; stered in portions during the day, if desired.
The following nonlimiting examples illustrate the inventors' preferred methods for preparing the compounds of the invention. For added clarity, complex chemical names describing compounds of Formula I are followed by structural abbre~iations, which are shown in braces, wherein the structural elements are as defined in the Table of Abbreviations above.

N-~N-~N-~N-~(Phenylmethoxy)carbonyl]-L-histidyll-O-(phenylmethyl)-L-tyrosyll-O-(phenylmethyl)-L-seryll-D-alanine meth~l ester ~Cbz-His-Tyr(OBn)-Ser(OBn)-D-Ala-~02Me }

CA 02204l44 l997-04-30 W O96/17861 PCTrUS95/14010 Step 1: Boc-Ser(O~n)-D-Ala-CO2~
To a solution of Boc-Ser(OBn) (4.12 g, 13.95 mmol) in EtOAc (100 mL) at 0 C was added HOBT ~2.35 g, 15.35 mmol) and DCC (3.17 g, 15.35 mmol). D-Alanine methyl ester hydrochloride (1.95 g, 13.95 mmol) was erl followed by Et3N (2.14 mI" 15. 35 mmol). The mixture was allowed to warm to room temperature and stirred overnight. The mixture was filtered, and the filtrate was washed with saturated aqueous NaHCO3, brine, dried (MgSO4), and concentrated. Flash chromatography (40~ EtOAc/h.o~c~ne) gave 2. 60 g of the title compound as a colorless oil; CI-MS 381 (m+1).

Step 2: Ser(OBn)-D-Ala-CO2Me-TFA
To a solution of Boc-Ser(OBn)-D-Ala-CO2Me from Step 1 above (2.44 g, 6.41 mmol) in CH2Cl2 (10 mL) was added TFA (3 mL). The solution was stirred for 6 hours at room temperature, then concentrated. The residue was taken up in CH2Cl2 and reconcentrated. After trituration with ether, the title compound was obt~;ne~
as a white solid, mp 109-110~C.

Step 3: Boc-Tyr(OBn)-Ser(OBn)-D-Ala-CO2Me To a solution of Boc-Tyr(OBn) (0. 94 g, 2. 54 mmol) in DMF (10 mL) at 0~C was added HOBT (o. 47 g, 3.04 mmol) and DCC (0.63 g, 3.04 mmol). Ser(OBn)-D-Ala-CO2Me TFA from Step 2 above (1.0 g, 2.54 mmol) was added followed by Et3N (0.42 mL, 3.04 mmol). The mixture was allowed to warm to room temperature and stirred overnight. The mixture was filtered, and the filtrate was diluted with CHC13, washed twice with saturated aqueous NaHC03, brine, dried (MgS04), and concentrated. Flash chromatography (50~ EtOAc/hexane) gave 1. 35 g of the title compound as a white solid, mp 132-133~C; CI-MS 634 (m+1).

W O96/17861 PCT~US95/14010 Step 4: Tyr(QBn)-Ser(OBn)-D-Ala-C02Me TFA
Prepared according to Step 2 above, substituting Boc-Tyr(OBn)-Ser(OBn)-D-Ala-C02Me for Boc-Ser(OBn)-D-Ala-C02Me. The title compound was obtained as a white solid; CI-MS 534 (m+1).

Step 5: Cbz-His-Tyr(OBn)-Ser(OBn)-D-Ala-C02Me Prepared according to Step 3 above, by substituting Cbz-His for Boc-Tyr(OBn) and Tyr(OBn)-Ser(OBn)-D-Ala-C02Me TFA for Ser(OBn)-D-Ala-C02Me~TFA.
The title compound was obtained as a white solid, mp 188-191~C.
Anal. Calc. for C44H48N609 H20:
C, 64.22; H, 6.12; N, 10.21;
Found: C, 64.15; H, 5.99; N, 10.17.

N-rN-rN-[N- r (Phenylmethoxy)carbonyll-L-histidyl]-O-(phenylmethyl)-L-tyrosyll-O-(phenylmethyl)-L-seryll-D-alanine monohydrochloride ~Cbz-His-Tyr(OBn)-Ser(OBn)-D-Ala HCl}
To a suspension of Cbz-His-Tyr(OBn)-Ser(OBn)-D-Ala-C02Me from Example 1 abo~e (0.43 g, 0.53 mmol) in THF (10 mL) and MeOH (3 mL) at 0~C was added O.lN LiOH
(5.9 mL). The mixture was stirred for 6 hours at O C
and then concentrated. Water was added and the pH was adjusted to 4-5 by the addition of lN HCl. The mixture was filtered, and the precipitate was collected and dried to afford 0.37 g of the title compound as a white solid, mp 190-197~C; FAB-MS 791 (m+1).

CA 02204l44 l997-04-30 W O96/17861 PCTrUS95/14010 N- rN- rN- rN- r (Phenylmethoxy)carbonyll-L-histidyll-O-(phenylmethyl)-L-tyrosyll-O-(phenylme~hyl)-L-seryl]-L-tryptophan. methyl ester {Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-CO2Me}
Step 1: Boc-Tyr(OBn)-Ser(OBn)-CO2Me To a solution of Boc-Tyr(OBn) (1.88 g, 6.50 mmol) in EtOAc (30 mL) at 0 C was added HOBT hydrate (1.19 g, 7.80 mmol) followed by DCC (1.61 g, 7.80 mmol). A
solution of Ser(OBn)-C02Me TFA (2.1 g, 6.50 mmol) in EtOAc (20 mL) was added followed by Et3N (1.09 mL, 7.80 mmol). The mixture was allowed to warm to room temperature and stirred overnight. The mixture was filtered, diluted with EtOAc, and washed twice with saturated aqueous NaHCO3, brine, dried over MgSO4, and concentrated. Flash chromatography (40~ EtOAc/hexane) gave 2.67 g (73~) of the title compound as a white solid, mp 81-84~C.

Step 2: Boc-Tyr(OBn)-Ser(OBn) Prepared according to Example 2, by substituting Boc-Tyr(OBn)-Ser(OBn)-CO2Me for Cbz-His-Tyr(OBn)-Ser(OBn)-D-Ala-CO2Me. The title compound was obt~;ne~
as a white foam.
Step 3: Boc-Tyr(OBn)-Ser(OBn)-Trp-CO2Me Prepared according to Example 1, Step 3, by substituting Boc-Tyr(OBn)-Ser(OBn) for Boc-Tyr(OBn) and Trp-CO2Me HCl for Ser(OBn)-D-Ala-CO2Me TFA. The title compound was obt~tne~ as a white foam; FAB-MS 750 (m+1).

Step 4: Tyr(OBn)-Ser(OBn)-Trp-CO2Me TFA
Prepared according to Example 1, Step 2, by substituting Boc-Tyr(OBn)-Ser(OBn)-Trp-CO2Me for Boc-Ser(OBn)-D-Ala-CO2Me, and adding 2 equiv of thioanisole W O 96/17861 PCTrUS95/14010 in addition to TFA. The title compound was obtained as white solid.

Step 5: Cbz-His-TyrtOBn)-Ser(OBn)-Trp-CO2Me Prepared according to Example 1, Step 5, by substituting Tyr(OBn)-Ser(OBn)-Trp-CO2Me TFA for Tyr(OBn)-Ser(OBn)-D-Ala-CO2Me TFA. The title compound was obtained as a white foam; FA~-MS 920 (m+1).

N-rN-rN-rN- r (Phenylmethoxy)carbonyll-L-histidyl]-O-(phenylmethyl)-L-tyrosyll-O-(phenylmethyl)-L-seryl]-L-tryptophyll-D-alAn; n~m; de ~Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2}
Using an A~3I model 431A solid phase peptide synthesizer, Fmoc-NH-Rink resin (0.25 mMol scale) was treated with 20~ piperidine in NMP to afford NH2- Rink resin. Sequential coupling of Fmoc-protected D-Ala, Trp, Ser(OBn) and Tyr(OBn) (DCC and HOBT in NMP) and Fmoc deprotection (20~ piperidine in NMP) reactions were run using a fourfold excess of reagents in the coupling steps and traditional resin washing cycles to afford Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH-Rink resin.
This tetrapeptide resin was transferred to an uninstrumented reaction vessel and treated with a fourfold excess of Cbz-His, DCC and HOBT in DMF, shaking overnight at room temperature. After removal of excess reagents, the resulting substituted pentapeptide was cleaved from the resin by treatment with 50~ TFA in DCM at room temperature for 2.5 hours.
Evaporation of solvents, lyophilization and purification by reversed phase chromatography (Cl8-column, eluted with a 20-70~ gradient of MeCN in water (both solvents acidified with 0.1~ TFA)) afforded Cbz-Xis-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONX2 as its TFA
salt upon lyophilization. FAB-MS: 976 (m+1).

WO96/17861 PCT~S95/14010 Using analogous methods the following most preferred compounds of Formula I with carboxamides at the C-term;nll~ may be prepared:
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONH2, ES-MS 976 (m+l);
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONH2;
Cbz-His-Tyr-Ser(OBn)-Trp-D-Ala-CONH2, FAB-MS 886 (m+l);
Cbz-His-D-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2, FAB-MS 976 (m+l);
Cbz-His-Phe-Ser(OBn)-Trp-D-Ala-CONH2, ES-MS 870 (m+l);
Cbz-His-Tyr(OBn)-Ser-Trp-D-Ala-CONH2, FAB-MS 886 (m+l);
Cbz-D-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2, FAB-MS 976 (m+l);
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-CONH2, ES-MS 905 (m+l);
Cbz-His-Tyr(OBn)-Ser(OBn)-Ala-D-Ala-CONH2, ES-MS
861 (m+l);
Cbz-His-Phe-Ser(OBn)-Trp-Ala-CONH2; ES-MS 870 (m+l);
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONH2;
Cbz-His-Tyr(OPO3H2)-Ser(OBn)-Trp-DAla-CONH2, ES-MS 966 (m+l);
Cbz-His-p(CH2PO3H2)Phe-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-p(CH2PO3Et2)Phe-Ser(OBn)-Trp-DAla-CONH2, ES-MS 1021 (m+l);
Cbz-His-p(CF2PO3H2)Phe-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-Glu-Ser(OBn)-Trp-DAla-CONH2, ES-MS 852.3 (m+l);
Cbz-His-Asp-Ser(OBn)-Trp-DAla-CONH2, ES-MS 838.6 (m+l);

Cbz-His-Tyr(OBn)-Ser(OPO3H2)-Trp-DAla-CONH2, FAB-MS 966.2 (m+1); and Cbz-His-Tyr(OPO3H2)-Ser(OBn)-Trp-CONH2, ES-MS 895.5 (m+l).

N~- rN- rN- rN- rN- r (Phenylmethoxy)carbonyll-L-histidyl]-O-(phenylmethyl)-L-tyrosyll-L-cy8teinyl-L-tryptophyll-D-al~n;n~m;de {Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CONH2}
Sequential coupling and deprotection of Fmoc-protected D-Ala, Trp, Cys(STr), Tyr(OBn) and Cbz-His by the solid phase method described in Example 4, followed by treatment with 60~ TFA in DCM for 3.5 hours at room temperature gave crude Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CONH2 upon evaporation of solvents and lyophilization.
Purification was accomplished by reversed phase chromatography on a C18 column, eluted with a 25 to 75~
gradient of MeCN in water (both solvents acidified with 0.1~ TFA) to give the TFA salt of the title compound upon lyophilization. ES-MS: 902 (m+1).
Using analogous methods the following most preferred compounds of Formula I which contain Cys and a carboxamide at the C-term;nl~s may be prepared:
Cbz-His-Tyr(OBn)-Cys-Trp-Ala-CONH2;
Cbz-His-Tyr(OBn)-Cys-Trp-Gly-CONH2;
BnNHCO-His-Tyr(OBn)-Cys-Trp-D-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Gly-CONH2;
Cbz-Cys-Tyr(OBn)-Ser(OBn)-Trp-DAla-CONH2, FAB-MS 942.6 (m+1); and Cbz-His-Tyr (OP03H2) -Cys-Trp-DAla-CONH2 .

The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as W O96/17861 PCTrUS95/14010 illustrati~e and not restrictive. The scope of the invention iQ, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the m~n;ng and range of equivalency of the claims are to be embraced within their scope.

W O 96/17861 PCTrUS95/14010 ~q~ LISTING

(1) GENERAL INFORMATION:
(i) APPLICANT: Warner-Lambert Company (il) TITLE OF INVENTION: Substituted Tetra- and Pentapeptide Inhibitors of Protein:
Farnesyl Transferase (ili) NUMBER OF ~Qu~N~: 59 (iv) CORR~PONDEN OE ADDRESS:
(A) ~nn~r~S~r~ Warner-Lambert Company (B) 5'1'K~;~1: 2800 Plymouth Rd.
(C) CITY: Ann Arbor (D) STATE: MI
(E) Co~N'l'~Y: US
(F) ZIP: 48105 (v) COM~ul~K READABLE FORM:
~A) MEDIUM TYPE: Floppy di8k B) COh~ul~K: IBM PC compatlble C) OPERATING ~Y~1~M: PC-DOS/MS-DOS
,D) SOFTWARE: PatentIn Release 1.0,Ver. 1.25 (vi) ~U~Rr~'NT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Crissey, Todd (B) REGISTRATION NUMBER: 37807 (C) REFEREN OE /DOCKET NUMBER: PD-4631PCT
(lx) Tr~'r~OMMUNICATION INFORMATION:
(A) TEL~)h~: 313 996-7530 (B) TELEFAX: 313 996-1553 =

W O96/17861 PCTrUS95/14010 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQ~ CHARACTERISTICS:
(A) L~Gi~: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Cys Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) L~N~l~: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Cys Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Cys Xaa Xaa Xaa W O96/17861 PCTrUS95/14010 (2) INFORMATION FOR SEQ ID NO:4:
(i) SE~u~N~ CHARACTERISTICS:
(A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~ DESCRIPTION: SEQ ID NO:4:
Cy8 Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:5:
(i) SEQu~N~ CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
His Xaa Xaa Trp Ala (2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
His Xaa Xaa Trp Ala _ W O96/17861 PCTrUS95/14010 (2) INFORMATION FOR SEQ ID NO:7:
(i) SEQu~N~ CHARACTERISTICS:
(A) L~N~l~: 5 amino acids (~) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~ ~ DBSCRIPTION: SEQ ID NO:7:
His Xaa Xaa Trp Ala (2) INFORMATION FOR SEQ ID NO:8:
(i) SEQ~N~ CHARACTERISTICS:
(A) L~:N~l~: 5 amino acidc (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~ ~ DESCRIPTION: SEQ ID NO:8:
His Xaa Xaa Trp Ala (2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) L~Gl~: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
His Xaa Xaa Trp Ala W O96/17861 PCT~US95/14010 (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~N~ DESCRIPTION: SEQ ID NO:10:
His Xaa Xaa Trp Ala (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQ~ CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~:N~: DESCRIPTION: SEQ ID NO:11:
His Xaa Xaa Trp Gly (2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
His Xaa Xaa Trp Gly W O96/17861 PCT~US95/14010 r ( 2) INFORMATION FOR SEQ ID NO:13:
(i) SEQ~NC~ CHARACTERISTICS:
(A) ~:N~l~: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
His Xaa Xaa Trp Gly (2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) L~N~ 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQu~NC~: DESCRIPTION: SEQ ID NO:14:
His Xaa Xaa Trp Gly (2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) L~N~l~: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
His Xaa Xaa Trp Gly W O96/17861 PCTrUS95tl4010 (2) INFORMATION FOR SEQ ID NO:16:
(i) SEQu~N~ CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~N~ DESCRIPTION: SEQ ID NO:16:
His Xaa Xaa Trp Gly (2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
His Phe Xaa Trp Ala (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
His Xaa Xaa Trp W O96/17861 PCTrUS95/14010 r ( 2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~NC~ DESCRIPTION: SEQ ID NO:19:
His Xaa Xaa Trp (2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) L~:N~l~: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
His Xaa Cys Trp (2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear ~ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
His Xaa Cys Trp W O96/17861 PCTrUS95/14010 (2) INFORM~TION FOR SEQ ID NO:22:
(i) S~Qu~N~ CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
His Xaa Xaa Trp Ala (2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
His Xaa Xaa Trp Ala (2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: S amino acidc (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
His Xaa Xaa Trp Ala W O 96/17861 PCT~US95114010 (2) INFORMATION FOR SEQ ID NO:25:
(i) S~Q~N~ CHARACTERISTICS:
(A) L~N~ln: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
His Xaa Xaa Trp Ala (2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) L~ln: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
His Xaa Xaa Trp Ala (2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) L~N~ln: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SE~u~N~ DESCRIPTION: SEQ ID NO:27:
His Xaa Xaa Trp Ala W O96/17861 PCT~US95/14010 (2) INFORMATION FOR SEQ ID NO:28: A
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~N~ DESCRIPTION: SEQ ID NO:28:
His Xaa Xaa Trp Gly (2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCB CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
His Xaa Xaa Trp Gly (2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
His Xaa Xaa Trp Gly WO96/17861 PCT~S95/14010 ~ (2) INFORM~TION FOR SEQ ID NO:3l:
(i) SE~N~ CHARACTERISTICS:
(A) ~ENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECU~E TYPE: peptide (xi) SEQu~N~ DESCRIPTION: SEQ ID NO:31:
His Xaa Xaa Trp Gly l 5 (2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPO~OGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
His Xaa Xaa Trp Gly l 5 (2) INFORM~TION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MO~ECU~E TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
His Xaa Xaa Trp Gly l 5 W O96/17861 PCTrUS95/14010 (2) INFORMATION FOR SEQ ID NO:34:
(i) SEQ~ CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SE~u~ DESCRIPTION: SEQ ID NO:34:
His Xaa Cys Trp Ala (2) INFORMATION FOR SEQ ID NO:35:
(i) SEQu~N~ CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
His Xaa Cys Trp Ala (2) INFORMATION FOR SEQ ID NO:36:
(i) SEQ~ CHARACTERISTICS:
(A) ~ENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECU~E TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
His Xaa Cys Trp Ala W O96/17861 PCTrUS95/14010 (2) INFORMP~TION FOR SEQ ID NO:37:
(1) SE~U~C~ CHARACTERISTICS: .
(A) L~N~-1~: 5 amino acids (B) TYPE amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE peptide (Xi) SEQUENCE DESCRIPTION SEQ ID NO:37:
His Xaa Cys Trp Ala (2) INFORM~TION FOR SEQ ID NO:38:
(i) SE~U~NC~ CHARACTERISTICS
(A) L~N~1~ 5 amino acids (B) TYPE amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION SEQ ID NO: 38:
HiS Xaa Cys Trp A1a (2) INFORMATION FOR SEQ ID NO:39:
(i) SEQUENCE CHARACTERISTICS
(A) L~1~ 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE peptide (Xi) SEQUENCE DESCRIPTION SEQ ID NO:39:
His Xaa Cys Trp Ala W O96/17861 PCTrUS95/14010 (2) INFORM~TION FOR SEQ ID NO:40:
(i) SEQUBNCE CHARACTERISTICS:
(A) ~N-~-1n: 5 amino acid~
(B) TYPE: amino acid (D) TOPO~OGY: linear (ii) MO~ECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:
His Xaa Cys Trp Gly (2) INFORMATION FOR SEQ ID NO:41:
(i) SEQUENCE CHARACTERISTICS:
(A) L~'1n: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
His Xaa Cys Trp Gly (2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) L~N~1n: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MO~ECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
His Xaa Cys Trp Gly WO96/17861 PCT~S95/14010 -5l-(2) INFORMATION FOR SEQ ID NO:43:
(i) SEQu~ CHARACTERISTICS:
(A) L~N~ln: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) S~Q~N~ DESCRIPTION: SEQ ID NO:43:
His Xaa Cy8 Trp Gly l 5 (2) INFORMATION FOR SEQ ID NO:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SBQUENCE DESCRIPTION: SEQ ID NO:44:
His Xaa Cys Trp Gly l 5 (2) INFORMATION FOR SEQ ID NO:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~N~ DESCRIPTION: SEQ ID NO:45:
His Xaa Cys Trp Gly l 5 W O 96tl7861 PCTrUS95/14010 (2) INFORMATION FOR SEQ ID NO:46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQu~ DESCRIPTION: SEQ ID NO:46:
His Xaa Cys Trp Ala (2) INFORMATION FOR SEQ ID NO:47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:
His Xaa Cys Trp Ala (2) INFORMATION FOR SEQ ID NO:48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:
His Xaa Cys Trp Ala WO96117861 PCT~S95/14010 (2) INFORMATION FOR SEQ ID NO:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 Am;no acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQu~N~ DESCRIPTION: SEQ ID NO:49:
His Xaa Cys Trp Ala l 5 (2) INFORMATION FOR SEQ ID NO:50:
(i) SEQ~N~ CHARACTERISTICS:
(A) LENGTH: 5 ~mino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:
His Xaa Cy5 Trp Ala l 5 (2) INFORMATION FOR SEQ ID NO:51:
(i) SEQ~ ~ CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:
His Xaa Cys Trp Ala l 5 WO96/17861 PCT~S95114010 (2) INFORMATION FOR SEQ ID NO:52:
~i) SEQu~N~ CHARACTERISTICS:
(A) ~ENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:
His Xaa CYB Trp Gly l 5 (2) INFORMATION FOR SEQ ID NO:53:
(i) SEQUENCE CHARACTERISTICS:
~A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
His Xaa Cys Trp Gly l 5 ~2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULB TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
His Xaa Cys Trp Gly l 5 _ (2) INFORMATION FOR SEQ ID NO:55:
(i) SEQu~ CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~N~ DESCRIPTION: SBQ ID NO:55:
His Xaa Cys Trp Gly (2) INFORMATION FOR SEQ ID NO:56:
(i) SEQUENCE CHARACTERISTICS:
(A) L~N~ln: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:
His Xaa Cys Trp Gly (2) INFORMATION FOR SEQ ID NO:57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
His Xaa Cys Trp Gly W O96tl7861 PCTrUS95114010 (2) INFORMATION FOR SEQ ID NO:58:
(i) SEQu~N~ CHARACTERISTICS:
(A) L~ 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~N~ DESCRIPTION: SEQ ID NO:58:
His Xaa Xaa Trp (2) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) L~l~: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQ~N~ DESCRIPTION: SEQ ID NO:59:
Tyr Lys Cys Val Ile Met _

Claims (24)

What is claimed is:
1. A compound of the Formula I:

I

wherein n = 1 or 2;
A = -COR2, -CO2R2, -CONHR2, -CSR2, -C(S)R2, -C(S)NHR2, or H;
wherein R2 is alkyl, -(CH2)m-cycloalkyl, - (CH2)m-aryl, -(CH2)m-heteroaryl, and m = 0, 1, 2, or 3;
R = independently H or Me;
Y = independently H or Me;
Z = independently H or Me;

R4 = wherein R4' = H or Me;
-SR4'', wherein R4'' = H, alkyl, trityl, or heteroaryl;
R5 = wherein R5' = H, -OH, -O-alkyl, alkyl, -CO-aryl, - (CH2)m-aryl, -O(CH2)m-cycloalkyl, -O(CH2)m-aryl, - O(CH2)m-heteroaryl, - OPO3R5''2, -CH2PO3R5''2, - CF2PO3R5''2, or -CFHPO3R5''2, wherein R5 is located at either the ortho, meta, or para position and R5"" = H, alkyl, alkylaryl, or cyclohexyl, and m is as described above;
-COOR7, wherein R7 = H, Me, t-butyl, or benzyl;
-SR8, wherein R8 = H or trityl;
R6 = -OR6', wherein R6' = H, benzyl, -PO3R5''2, wherein R5'' is as described above;
-CH2-R9, wherein R9 = -PO3R5''2, wherein R5 is as described above;
-SR6'', wherein R6'' = H, benzyl, or trityl;
C = Gly, Ala, Val, Leu, Ile, Phe, Tyr, Tyr(OMe), Pgl, homoPhe, Trp, Trp(Me), or Trp(CHO);
D = Gly, Ala, or absent;
E = -COOH, -CONH2, -CONHNH2, -CONHR10, or -CO2R10, wherein R10 = H, alkyl, -(CH2)m-cycloalkyl, -(CH2)m-aryl, or -(CH2)m-heteroaryl, and m is as described above; an isomer or a pharmaceutically acceptable salt thereof.
2. A compound according to Claim 1 which is a compound of Formula II:

II

wherein n' = 1 or 2;
A' = -COR2', -CO2R2', or -CONHR2', wherein R2' = alkyl, -(CH2)m-aryl, -(CH2)m-heteroaryl, and m = 0, 1, or 2;
R = independently H or Me;
Y = independently H or Me;

Z = independently H or Me;

R12 = wherein R12' = H or Me;
-SR12'', wherein R12 " = H or alkyl;

R13 = wherein R13' = H, -OH, -O-alkyl, alkyl, -CO-aryl, benzyl, -O-benzyl, wherein R13' is located at either the ortho, meta, or para position;
-OPO3R14 2, -CH2PO3R14 2, or -CF2PO3R14 2, wherein R14 = H or alkyl;
-COOR15, wherein R15 = H, Me, t-butyl, or benzyl;
R16 = -OR16', wherein R16' = H, benzyl, -PO3R14 2, wherein R14 is as described above;
-CH2-R16'', wherein R16'' = -PO3R14 2, wherein R14 is as described above;
-SR16''', wherein R16''' = H or benzyl;
C' = Ala, Trp, Trp(Me), or Trp(CHO);
D' = Gly, Ala, absent;
E' = -COOMe, -CONH2, -CONHNH2, -COOH, or -CONH-alkyl;
an isomer or a pharmaceutically acceptable salt thereof.
3. A compound according to Claim 1 wherein A is Cbz, BnNHCO, R is H and n is 1 or 2.
4. A compound according to Claim 1 wherein R4 is , - SH and Y is H.
5. A compound according to Claim 1 wherein R5 is wherein R5' = H, -OH, -OBn, -OPO3H2, -CH2PO3H2, -CH2PO3Et2, -CF2PO3H2, or wherein R5 = -COOH, and Z
is H.
6. A compound according to Claim 1 wherein R6 is -OBn, -OH, -SH, or -OPO3H2.
7. A compound according to Claim 1 wherein C is Trp or Ala.
8. A compound according to Claim 1 wherein D is Gly, Ala, or absent.
9. A compound according to Claim 1 wherein E is -COOH, -CONH2, -COOMe, -CONHEt, -CONHNH2, or -CONHMe.
10. A compound according to Claim 1 which is Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2;
Cbz-Cys-Tyr(OBn)-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-Tyr(OPO3H2)-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-p(CH2PO3H2)Phe-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-p(CH2PO3Et2)Phe-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-p(CF2PO3H2)Phe-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-Glu-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-Asp-Ser(OBn)-Trp-DAla-CONH2;
Cbz-His-Tyr(OBn)-Ser(OPO3H2)-Trp-DAla-CONH2;
Cbz-His-Tyr(OPO3H2)-Cys-Trp-DAla-CONH2; and Cbz-His-Tyr(OPO3H2)-Ser(OBn)-Trp-CONH2.
11. A compound according to Claim 1 selected from the group consisting of:
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHMe;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHEt;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHNH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CO2Me;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHMe;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHEt;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHNH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CO2Me;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Ala;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHMe;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHEt;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHNH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-C02Me; and Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-Gly.
12. A compound according to Claim 1 selected from the group consisting of:
Cbz-His-Tyr-Ser(OBn)-Trp-D-Ala-CONH2;
Cbz-His-Tyr(OBn)-Ser-Trp-D-Ala-CONH2;
Cbz-His-Phe-Ser(OBn)-Trp-D-Ala-CONH2;
Cbz-His-Phe-Ser(OBn)-Trp-Ala-CONH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-Ala-D-Ala-CONH2;
Cbz-D-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2;
and Cbz-His-D-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2.
13. A compound according to Claim 1 selected from the group consisting of:
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-CO2Me;
Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-CONH2;
Cbz-His-Tyr(OBn)-Ser(OBn)-D-Ala-CO2Me;

Cbz-His-Tyr(OBn)-Ser(OBn)-D-Ala;
Cbz-D-His-Tyr(OBn)-Ser(OBn)-Trp-CO2Me;
Cbz-His-D-Tyr(OBn)-Ser(OBn)-Trp-CO2Me;
Cbz-His-Tyr(OBn)-Cys-Trp-CONH2; and BnNHCO-His-Tyr(OBn)-Cys-Trp-CONH2.
14. A compound according to Claim 1 selected from the group consisting of:
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHMe;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHEt;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CONHNH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-CO2Me;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHMe;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHEt;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CONHNH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala-CO2Me;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Ala;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHMe;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHEt;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CONHNH2;
BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly-CO2Me;
and BnNHCO-His-Tyr(OBn)-Ser(OBn)-Trp-Gly.
15. A compound according to claim 1 selected from the group consisting of:
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CONH2;
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CONHMe;
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CONHEt;

Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CONHNH2;
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala-CO2Me;
Cbz-His-Tyr(OBn)-Cys-Trp-D-Ala;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala-CONH2;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala-CONHMe;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala-CONHEt;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala-CONHNH2;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala-CO2Me;
Cbz-His-Tyr(OBn)-Cys-Trp-Ala;
Cbz-His-Tyr(OBn)-Cys-Trp-Gly-CONH2;
Cbz-His-Tyr(OBn)-Cys-Trp-Gly-CONHMe;
Cbz-His-Tyr(OBn)-Cys-Trp-Gly-CONHEt;
Cbz-His-Tyr(OBn)-Cys-Trp-Gly-CONHNH2;
Cbz-His-Tyr(OBn)-Cys-Trp-Gly-CO2Me; and Cbz-His-Tyr(OBn)-Cys-Trp-Gly.
16. A compound according to Claim 1 selected from the group consisting of:
BnNHCO-His-Tyr(OBn)-Cys-Trp-D-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Cys-Trp-D-Ala-CONHMe;
BnNHCO-His-Tyr(OBn)-Cys-Trp-D-Ala-CONHEt;
BnNHCO-His-Tyr(OBn)-Cys-Trp-D-Ala-CONHNH2;
BnNHCO-His-Tyr(OBn)-Cys-Trp-D-Ala-CO2Me;
BnNHCO-His-Tyr(OBn)-Cys-Trp-D-Ala;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Ala-CONH2;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Ala-CONHMe;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Ala-CONHEt;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Ala-CONHNH2;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Ala-CO2Me;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Ala;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Gly-CONH2;
BnNHCO-His-Tyr(OBn)-CyS-Trp-Gly-CONHMe;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Gly-CONHEt;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Gly-CONHNH2;
BnNHCO-His-Tyr(OBn)-Cys-Trp-Gly-CO2Me; and BnNHCO-His-Tyr(OBn)-Cys-Trp-Gly.
17. A method of treating tissue proliferative diseases comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
18. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
19. A method of treating cancer comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
20. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 2 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
21. A method of treating restenosis comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
22. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 10 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
23. A process for the preparation of compounds of Formula I according to Claim 1, or a pharmaceutically acceptable salt thereof, comprising the steps of employing solid phase support technology and sequentially coupling peptide building blocks by utilizing a solid phase peptide synthesizer, cleaving coupled building blocks from the solid phase support and optionally modifying the C-terminal of the coupled building blocks in solution phase to afford a compound of Formula I or a pharmaceutically acceptable salt thereof.
24. A process for the preparation of compounds of Formula I according to Claim 1, or a pharmaceutically acceptable salt thereof, comprising the steps of employing solution phase technology and sequentially coupling peptide building blocks to afford a compound of Formula I
or a pharmaceutically acceptable salt thereof.
CA002204144A 1994-12-09 1995-10-27 Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase Abandoned CA2204144A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35347394A 1994-12-09 1994-12-09
US353,473 1994-12-09

Publications (1)

Publication Number Publication Date
CA2204144A1 true CA2204144A1 (en) 1996-06-13

Family

ID=23389273

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002204144A Abandoned CA2204144A1 (en) 1994-12-09 1995-10-27 Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase

Country Status (4)

Country Link
JP (1) JPH10510261A (en)
AU (1) AU3971295A (en)
CA (1) CA2204144A1 (en)
WO (1) WO1996017861A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE550019T1 (en) 2005-05-17 2012-04-15 Merck Sharp & Dohme CIS-4-Ä(4-CHLOROPHENYL)SULFONYLÜ-4-(2,5-DIFLUOROPHENYL)CYCLOHEXANEPROPANE ACID FOR THE TREATMENT OF CANCER
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007121484A2 (en) 2006-04-19 2007-10-25 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (en) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Amide substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors
JP5330274B2 (en) 2007-03-01 2013-10-30 ノバルティス アーゲー PIM kinase inhibitor and method of use thereof
EP2152700B1 (en) 2007-05-21 2013-12-11 Novartis AG Csf-1r inhibitors, compositions, and methods of use
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
JP6073677B2 (en) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Fused heterocyclic compounds and their use
CN102638981B (en) 2009-10-14 2015-07-22 默沙东公司 Substituted piperidines that increase p53 activity and the uses thereof
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011115725A2 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
JP2014514321A (en) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション Insulin-like growth factor 1 receptor inhibitor
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
RU2660349C2 (en) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Compositions and methods for treatment of malignant tumour
BR112015013611A2 (en) 2012-12-20 2017-11-14 Merck Sharp & Dohme compound and pharmaceutical composition
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US9266824B2 (en) 2014-01-13 2016-02-23 Warsaw Orthopedic, Inc. Methods and compositions for making an amino acid triisocyanate
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
KR20190140454A (en) 2017-04-13 2019-12-19 아두로 바이오테크 홀딩스, 유럽 비.브이. Anti-SIRP alpha antibody
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528486A2 (en) * 1991-08-16 1993-02-24 Merck & Co. Inc. Non-substrate inhibitors of farnesyl protein transferase
CA2173590A1 (en) * 1993-10-25 1995-05-04 Gary Louis Bolton Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase

Also Published As

Publication number Publication date
JPH10510261A (en) 1998-10-06
WO1996017861A1 (en) 1996-06-13
MX9703208A (en) 1997-07-31
AU3971295A (en) 1996-06-26

Similar Documents

Publication Publication Date Title
AU682906B2 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
CA2204144A1 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
AU681454B2 (en) Substituted DI- and tripeptide inhibitors of protein:farnesyl transferase
AU699629B2 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
TW409129B (en) Factor Xa inhibitors
WO2001002424A2 (en) Peptide boronic acid inhibitors of hepatitis c virus protease
US5830868A (en) Substituted DI- and tripeptide inhibitors of protein: farnesyl transferase
US5763577A (en) Substituted tetra- and pentapeptide inhibitors of protein: farnesyl transferase
PT92496A (en) PROCESS FOR THE PREPARATION OF DIPEPTIDE DERIVATIVES WITH ACKNOWLEDGE OF ENZYMES, AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MXPA97003208A (en) Tetra-y pentapeptidos substituidos deproteina inhibitors, farnesil transfer
JP3009718B2 (en) New peptides, their production methods and applications
JP3009719B2 (en) New peptides, their production methods and applications
JP3012291B2 (en) Novel peptide, its production method and use
JP2965682B2 (en) New peptides, their production methods and applications
JP3009720B2 (en) New peptides, their production methods and applications
JP2965683B2 (en) Novel peptide, method for producing it and use
JPH07316193A (en) Peptide derivative and use thereof
JP3086235B2 (en) New peptides and applications
JP3012292B2 (en) New peptides, their production methods and applications
JP3031692B2 (en) Novel peptide, method for producing it and use
JPH04264097A (en) Peptide derivative and it's use
JPH0812594A (en) Angiotensin i converting enzyme inhibitor peptide derivative

Legal Events

Date Code Title Description
FZDE Dead